KCNA3 and psoriasis: Moreover, selective Kv1.3 inhibitors have shown efficacy in preclinical animal models [48–50], and one inhibitor, Dalazatide, is now in clinical trials for psoriasis [51], suggesting that Kv1.3 may indeed be a promising therapeutic target in chronically activated T-cell disorders.